{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T03:40:43Z","timestamp":1777261243104,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.aed.2026.01.014","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:04:16Z","timestamp":1770134656000},"page":"360-364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multiple Vertebral Fractures After One Dose of Denosumab"],"prefix":"10.1016","volume":"13","author":[{"given":"Jaime Leigh","family":"Ryan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-9629","authenticated-orcid":false,"given":"Leslie S.","family":"Eldeiry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.aed.2026.01.014_bib1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.aed.2026.01.014_bib2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ecl.2021.08.002","article-title":"Treatment of hypercalcemia of malignancy","volume":"50","author":"Chakhtoura","year":"2021","journal-title":"Endocrinol Metab Clinic North America"},{"issue":"5","key":"10.1016\/j.aed.2026.01.014_bib3","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jbmr.1570","article-title":"Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective","volume":"27","author":"Boonen","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.aed.2026.01.014_bib4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ecl.2024.08.002","article-title":"Prevention and management of denosumab discontinuation rebound fractures","volume":"53","author":"Jain","year":"2024","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"10.1016\/j.aed.2026.01.014_bib5","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.aed.2026.01.014_bib6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","author":"Lamy","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.aed.2026.01.014_bib7","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.aed.2026.01.014_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","article-title":"Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates","volume":"103","author":"Tripto-Shkolnik","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"10.1016\/j.aed.2026.01.014_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jocd.2021.01.006","article-title":"Efficacy of antiosteoporotic medications in patients with rebound-associated fractures after denosumab discontinuation","volume":"24","author":"Anastasilakis","year":"2021","journal-title":"J Clin Densitom"},{"issue":"9","key":"10.1016\/j.aed.2026.01.014_bib10","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"Fractures after denosumab discontinuation: a retrospective study of 797 cases","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J Bone Mineral Res"},{"key":"10.1016\/j.aed.2026.01.014_bib11","first-page":"dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"26","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.aed.2026.01.014_bib12","series-title":"Xgeva and Prolia Prescribing Information","year":"2025"},{"issue":"3","key":"10.1016\/j.aed.2026.01.014_bib13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ejendo\/lvaf013","article-title":"Denosumab withdrawal increases vertebral fracture and mortality risk compared with zoledronate","volume":"192","author":"Lu","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.aed.2026.01.014_bib14","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00198-024-07139-9","article-title":"A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis","volume":"35","author":"Kumar","year":"2024","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.aed.2026.01.014_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","article-title":"Denosumab discontinuation","volume":"21","author":"S\u00f8lling","year":"2023","journal-title":"Curr Osteoporos Rep"},{"issue":"12","key":"10.1016\/j.aed.2026.01.014_bib16","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00198-024-07213-2","article-title":"One versus 2 years of alendronate following denosumab: the CARD extension","volume":"35","author":"Tsai","year":"2024","journal-title":"Osteoporos Int"},{"issue":"10","key":"10.1016\/j.aed.2026.01.014_bib17","doi-asserted-by":"crossref","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","article-title":"Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion?","volume":"109","author":"Grassi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.aed.2026.01.014_bib18","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40618-025-02542-3","article-title":"Early administration of romosozumab prevents rebound of bone resorption related to denosumab withdrawal in fractured post-menopausal women: a real-world prospective study","volume":"48","author":"Piasentier","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"10.1016\/j.aed.2026.01.014_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10731","article-title":"Discontinuation of denosumab: gradual decrease in doses preserves half of the bone mineral density gain at the lumbar spine","volume":"7","author":"Laroche","year":"2023","journal-title":"JBMR Plus"},{"issue":"4","key":"10.1016\/j.aed.2026.01.014_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.11005\/jbm.2022.29.4.217","article-title":"The role of bisphosphonates prior to denosumab treatment on rebound fractures: a mini review","volume":"29","author":"Inojosa","year":"2022","journal-title":"J Bone Metab"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T03:27:24Z","timestamp":1777260444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915726000159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3050915726000159"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2026.01.014","relation":{},"ISSN":["3050-9157"],"issn-type":[{"value":"3050-9157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple Vertebral Fractures After One Dose of Denosumab","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2026.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Association of Clinical Endocrinology.","name":"copyright","label":"Copyright"}]}}